Kurokawa T, Iwasa S, Kakinuma A
Biotechnology Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, Japan.
Thromb Res Suppl. 1990;10:83-9. doi: 10.1016/0049-3848(90)90382-m.
Murine hybrid hybridomas secreting bispecific monoclonal antibodies (bs mAbs) were constructed by fusing hybridomas secreting an anti-tissue plasminogen activator (tPA) or anti-urokinase (UK) mAb with hybridomas secreting a mAb which binds to human fibrin but not to fibrinogen. The bs mAbs reactive to both fibrin and PA (tPA or UK) were purified by affinity chromatography employing the respective antigen-coupled columns and characterized by fibrin-binding, amidolytic and fibrinolytic assays. Immunochemical conjugation of PAs and the bs mAbs did not impair the catalytic activity of PAs at all and made it possible to concentrate PAs on fibrin clot. Pretreatment of fibrin with the bs mAbs enhanced the fibrin-binding of PAs and the subsequent fibrinolysis.
通过将分泌抗组织纤溶酶原激活剂(tPA)或抗尿激酶(UK)单克隆抗体(mAb)的杂交瘤与分泌能与人纤维蛋白结合但不与纤维蛋白原结合的mAb的杂交瘤融合,构建了分泌双特异性单克隆抗体(bs mAbs)的小鼠杂交杂交瘤。对纤维蛋白和PA(tPA或UK)均有反应的bs mAbs通过使用各自抗原偶联柱的亲和色谱法进行纯化,并通过纤维蛋白结合、酰胺分解和纤维蛋白溶解试验进行表征。PA与bs mAbs的免疫化学偶联完全不损害PA的催化活性,并使得能够将PA浓缩在纤维蛋白凝块上。用bs mAbs对纤维蛋白进行预处理可增强PA与纤维蛋白的结合以及随后的纤维蛋白溶解作用。